Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
79.84
+1.10 (+1.40%)
Official Closing Price
Updated: 4:10 PM EDT, Apr 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
February 13, 2025
Via
The Motley Fool
Rosen Law Firm Encourages Merck & Co. Inc. Investors to Inquire About Securities Class Action Investigation – MRK
February 12, 2025
From
The Rosen Law Firm, P.A.
Via
Business Wire
Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes
February 12, 2025
This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments.
Via
Stocktwits
Gilead Sciences Beats Q4 EPS Forecast
February 11, 2025
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.
Via
The Motley Fool
Recent Filing Shows That Rep. Josh Gottheimer Sold Over $54K Worth of Merck & Co Stock
February 11, 2025
Via
Benzinga
Market Whales and Their Recent Bets on MRK Options
February 06, 2025
Via
Benzinga
Top 3 Health Care Stocks You'll Regret Missing This Month
February 06, 2025
Via
Benzinga
Why Merck Stock Is Plummeting Today
February 04, 2025
Via
The Motley Fool
Merck Stock Heads For 5th Day Of Losses As TD Cowen Downgrades On Gardasil Woes, But Retail Holds Strong
February 10, 2025
The HPV vaccine had been a key growth driver in China until last year when economic headwinds disrupted demand.
Via
Stocktwits
Merck: 4 No-Brainer Reasons to Buy This Dip
February 10, 2025
Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity.
Via
MarketBeat
Better High-Yield Dividend Stock: Pfizer vs. Merck
February 10, 2025
Via
The Motley Fool
Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
February 06, 2025
From
Merck & Co., Inc.
Via
Business Wire
Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
February 05, 2025
Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a lower-than-expected 2025 outlook.
Via
Benzinga
Uncover the latest developments among S&P500 stocks in today's session.
February 04, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
Via
Chartmill
Merck (MRK) Q4 2024 Earnings Call Transcript
February 04, 2025
MRK earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Looking for the most active stocks in the S&P500 index on Tuesday?
February 04, 2025
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Tuesday and discover the stocks that are dominating the trading activity and setting the pace for...
Via
Chartmill
Merck Retail Traders See Buying Opportunity As Stock Dives Toward Worst Day in 17 Years On Weak Guidance
February 04, 2025
Gardasil, its HPV vaccine, posted a 17% decline in sales to $1.55 billion, primarily due to lower demand in China.
Via
Stocktwits
Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below.
February 04, 2025
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Tuesday. Stay informed about the market activity below.
Via
Chartmill
Discover which S&P500 stocks are making waves on Tuesday.
February 04, 2025
Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.
Via
Chartmill
Why Merck (MRK) Stock Is Falling Today
February 04, 2025
Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by a...
Via
StockStory
Gapping S&P500 stocks in Tuesday's session
February 04, 2025
Curious about the market action on Tuesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Via
Chartmill
US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?
February 04, 2025
U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.
Via
Benzinga
Get insights into the top movers in the S&P500 index of Tuesday's pre-market session.
February 04, 2025
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Via
Chartmill
Merck Tops Q4 Earnings And Revenue Estimates
February 04, 2025
Merck came out with quarterly earnings of $1.72 per share.
Via
Talk Markets
Topics
Stocks / Equities
Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook
February 04, 2025
Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil shipment pause in China and forex impact.
Via
Benzinga
PayPal, Estée Lauder, UBS And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
February 04, 2025
Via
Benzinga
Merck’s (NYSE:MRK) Q4 Sales Top Estimates But Stock Drops
February 04, 2025
Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6.8% year on year to $15.62 billion. On the other hand, the company’s...
Via
StockStory
Merck Tops Q4 Forecasts, But Dow Jones Giant Dives On 2025 Guidance
February 04, 2025
Merck topped Wall Street's Q4 expectations Tuesday, but the stock is taking a hit on light guidance.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results
February 04, 2025
From
Merck & Co., Inc.
Via
Business Wire
Earnings Scheduled For February 4, 2025
February 04, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.